Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

Non-GAAP EPS Increased 22 Percent

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.

First-Quarter Highlights

-- Total revenue for the quarter grew 25 percent to $1.1 billion from

$883.2 million in same period a year ago. This increase was driven by

growth across all product lines, led by strong growth in sales of

treatments for lysosomal storage disorders and renal disease.

Genzyme's top line now includes sales of Aldurazyme(R) (laronidase),

which previously were recorded as joint venture revenue.

-- GAAP net income in the first quarter was $145.3 million, or $0.52 per

diluted share, compared with $158.2 million, or $0.57 per diluted

share. GAAP net income in this year's first quarter reflects an after-

tax charge of $56.5 million for the premium related to Genzyme's

strategic investment in Isis Pharmaceuticals Inc.

-- Non-GAAP net income increased 24 percent to $260.9 million, compared

with $210.7 million in the first quarter a year earlier. Non-GAAP

earnings increased 22 percent to $0.95 per diluted share from $0.78 per

diluted share in the first quarter last year.

-- Non-GAAP operating expenses decreased as a percentage of revenue,

reflecting global operating leverage.

-- Genzyme continued to generate significant cash from operations and to

reinvest in the future of the company. In the first quar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... 2015 , ... This is a professional and in-depth study ... of the industry including definitions, classifications, applications and industry chain structure. The Biophotonics ... analysis, and key regions development status. Development policies and plans are discussed as ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced ... The venture will bring the world’s most efficient gas dissolution technology to all ... technologies to both the industrial and municipal markets. With offices located in Sarasota, ...
(Date:7/27/2015)... ... July 27, 2015 , ... Visual Assay was named as ... top 100 most innovative technologies and services of the past year. More than 70 ... Software/Services category. The winners will be announced at the 2015 R&D 100 Awards Dinner ...
(Date:7/24/2015)... , July 24, 2015 ... equities: PDL BioPharma Inc. (NASDAQ: PDLI ), Arena ... STEM ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ... Free research report on PDL BioPharma can be accessed ... the NASDAQ Composite ended at 5,146.41, down 0.49%, the ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3BlueInGreen Brings Water Treatment Technology to Florida 2Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... its revolutionary Trusted LASIK Surgeons directory service and website ... resource for consumers seeking to improve their vision. What ... unique screening process ensuring that only those who are ... eye surgery in the United States are listed. Refractive ...
... Sciences Discovery,Fund (LSDF) has awarded nearly $4.7 million to ... and to support initial research into,three new vaccines for ... funded by Washington,s$350 million tobacco-lawsuit-settlement bonus,and provides essential funding ... WAVA core operations during ...
... Fuld & Company today announced that Wayne Rosenkrans, ... specializing in strategic gaming for the pharmaceutical and healthcare ... "We are excited to have Dr. Rosenkrans join ... accomplishment in the global pharmaceutical industry; government and academia ...
Cached Biology Technology:Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 2Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 3Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 4Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 5Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 6Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 7Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Fuld & Company Announces Appointment of MIT Fellow to Head Pharmaceutical Team's Strategic Gaming and Consulting Services 2
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... Identity science takes a giant leap forward with ... at the new $1.5 million per year Pedo-Biometrics Research ... ID, an Ottawa, Canada, company currently relocating operations to ... a variety of identification uses, from security to detecting ...
... a threatened species, population, or genotype to an area ... response to the threat of extinction resulting from climate ... BioScience by Mark W. Schwartz and his ... Working Group, an interdisciplinary group of scientists, researchers, and ...
... obesity and vitamin D deficiency may put people at even ... to new research from the Drexel University School of Public ... Care. Insulin resistance is a major risk factor for ... and is the seventh leading cause of death in the ...
Cached Biology News:Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 2Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 3Developing policy on moving threatened species called 'a grand challenge for conservation' 2Obesity plus low vitamin D may add up to a greater risk of diabetes 2
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Acetate Plate Sealers 100/Box...
QCPN...
... new MALDI O-TOF creates a new category ... orthogonal platform that has been licensed to ... of Manitoba. , As the first single ... and collisional cooling, the prOTOF 2000 represents ...
Biology Products: